Tuesday, 17 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News
Earnings Call

Niagen Bioscience Earnings Call: Key Takeaways

Niagen Bioscience is navigating a transitional 2026 investment year, focusing on new salt forms and pharmaceutical pipelines to offset current revenue declines and ingredient pricing pressure.

Full earnings call on the Alfa Finder USA YouTube channel · Open on YouTube ↗
Highlights
Revenue GrowthTotal sales $27.2M; True Niagen $23.3M (down 10%); Ingredients $3.8M.
Mgmt ConfidenceHigh for 2027 expansion; 2026 characterized as a foundational investment year.
Demand VisibilitySequential Q4 improvement expected; Watson's orders expected to return to normal.
Margin TrendsGross margin 62.9% vs 64.5% prior year due to product mix.
Op. LeverageS&M expense rose to 32% of sales from 25.8% prior year.
Pricing PowerPricing remains a hurdle for ingredient customers due to NMN competition.
Vol vs PriceGrowth driven by DTC volume; ingredient revenue impacted by order timing.
Segment GrowthDTC website grew 17% adjusted; distribution revenue lagged due to timing.
New ClientsAdded Walmart.com, 300 GNC locations, Sam's Club, and Restore Hyper Wellness.
Capex & Debt$69.5M cash, zero debt, $14.6M remaining on share repurchase authorization.
RegulatoryFDA lawsuit regarding NMN; pursuing IND-enabling studies for NB4168 drug candidate.
CommentaryFocusing on 'Better NAD' differentiation through scientific rigor and patent enforcement.
New LaunchesNano Cloud skincare, at-home injection kits, and upcoming 2027 salt form.

Growth

Total sales fell 10% to $27.2M; DTC website grew 13% (17% adjusted).

Outlook

Targeting 2027 for commercialization of lower-cost salt forms and first-in-human pharmaceutical trials.

Risks

Management pivoted on G&A/litigation costs, citing 'certain periods' without providing specific future dollar targets.

Source

The company's earnings call, NASDAQ: NAGE, and its 8-K filed with the SEC. Summary written with AI assistance from the call.

Read the 8-K ↗

Niagen Bioscience, Inc.: key numbers

Share price
$2.01Close, Nov 16
Market cap
$159M
Shares outstanding
79.2MLatest SEC cover page
Sector
Life Sciences
Industry
Medicinal Chemicals & Botanical ProductsSIC 2833

Today's reference numbers, updated daily. Not a valuation or a recommendation.

More from Niagen Bioscience, Inc.

All →
4:02 PM ET 10-Q
Financial Results ▶ Call

Niagen Bioscience Q3 2026 Results: Net Loss of $1.17M

Niagen Bioscience reported a net loss of $1.2 million for the third quarter of 2026, a significant decline from a $4.6 million profit in the prior year, driven by a 20% decrease in net sales. However, for the nine-month period, the company remained profitable with a net income of $6.1 million, bolstered by a $4.8 million gain from the sale of an operating segment.

Key figure
Net loss $1.17M
4:02 PM ET 8-K
Financial Results

Niagen Bioscience Financial Results

Niagen Bioscience reported Q3 2026 net sales of $27.2 million and a net loss of $1.2 million, while generating $2.6 million in operating cash flow. The company launched several new products including Niagen NanoCloud topical and an at-home injection kit, while expanding retail distribution through Walmart.com, GNC, and Sam's Club.

Term
Q3 2026

“During the third quarter, we navigated near-term commercial headwinds while continuing to generate positive adjusted EBITDA and $2.6 million in operating cash flow and make tangible progress across the Niagen platform. We advanced NB4168, expanded Tru Niagen distribution, established skincare as a permanent category, launched a more convenient ready-to-inject Niagen Plus product, and invested in brand awareness and long-term clinical research. As stated before, we view 2026 as an investment year, and believe the progress we are making across consumer health, ingredients, injectables, skincare, and pharmaceuticals provides a strong springboard for meaningful growth in 2027 and beyond.”

Rob Fried, Chief Executive Officer

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.